Tertiary lymphoid structures in lung adenocarcinoma: characteristics and related factors.
part-solid nodule
pure ground-glass nodule
solid nodule lung adenocarcinoma
solitary pulmonary nodule
tertiary lymphoid structure
Journal
Cancer medicine
ISSN: 2045-7634
Titre abrégé: Cancer Med
Pays: United States
ID NLM: 101595310
Informations de publication
Date de publication:
08 2022
08 2022
Historique:
revised:
15
12
2021
received:
04
11
2021
accepted:
18
12
2021
pubmed:
9
7
2022
medline:
11
8
2022
entrez:
8
7
2022
Statut:
ppublish
Résumé
Tertiary lymphoid structures (TLSs) are found in a variety of malignancies and affect the growth of tumors, but few studies have addressed their role in lung adenocarcinoma (LAC). We aimed to evaluate clinical features associated with TLSs in patients with LAC. A collection of resected pulmonary nodules in patients with LAC was retrospectively analyzed. TLSs were quantified by their number per square millimeter tumor area (density) and by the degree of lymphocyte aggregation (maturity) in each case. The correlation between TLS density and maturity and clinical features was calculated. A total of 243 patients were selected, of whom 219 exhibited TLSs. The occurrence of TLSs was correlated with computed tomography (CT) features as follows: pure ground-glass nodules (pGGNs) (n = 43) was associated with a lower occurrence rate than part-solid nodules (PSNs) (n = 112) and solid nodules (SNs) were (n = 88) (p = 0.037). TLS density was correlated with age and CT features. Poisson regression showed higher TLS density in PSNs and SNs than in pGGNs (incidence rate ratio [IRR]: 3.137; 95% confidence interval [CI]: 1.35-7.27; p = 0.008 and IRR: 2.44; 95% CI: 1.02-5.85; p = 0.046, respectively). In addition, TLS density was higher in patients aged under 60 years than in those aged over 60 years (IRR: 0.605; 95% CI: 0.4-0.92; p = 0.018). The maturity of TLSs was higher in patients with higher tumor stages (p = 0.026). We demonstrated distinct profiles of TLSs in early LAC and their correlations with CT features, age, and tumor stages, which could help understand tumor progression and management.
Identifiants
pubmed: 35801360
doi: 10.1002/cam4.4796
pmc: PMC9359870
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2969-2977Informations de copyright
© 2022 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Références
Front Oncol. 2021 Jul 26;11:693234
pubmed: 34381716
Oncol Lett. 2020 Sep;20(3):2655-2664
pubmed: 32782582
Nature. 2020 Jan;577(7791):549-555
pubmed: 31942075
Trends Immunol. 2014 Nov;35(11):571-80
pubmed: 25443495
Cancer Med. 2022 Aug;11(15):2969-2977
pubmed: 35801360
Nat Rev Rheumatol. 2017 Mar;13(3):141-154
pubmed: 28202919
Biomark Res. 2020 Apr 9;8:9
pubmed: 32308981
Aging (Albany NY). 2020 Feb 22;12(4):3451-3472
pubmed: 32087064
Nature. 2020 Jan;577(7791):561-565
pubmed: 31942071
Immunity. 2015 Sep 15;43(3):579-90
pubmed: 26341400
Radiology. 2012 Aug;264(2):590-6
pubmed: 22653188
Cell Mol Immunol. 2021 Apr;18(4):842-859
pubmed: 33139907
Mod Pathol. 2019 Jan;32(1):70-80
pubmed: 30154578
Melanoma Res. 2018 Jun;28(3):237-245
pubmed: 29538091
J Clin Oncol. 2008 Sep 20;26(27):4410-7
pubmed: 18802153
J Cardiothorac Surg. 2020 Aug 12;15(1):121
pubmed: 32782020
Cancers (Basel). 2020 Sep 16;12(9):
pubmed: 32947928
Biochim Biophys Acta Rev Cancer. 2020 Dec;1874(2):188443
pubmed: 33035642
Zhongguo Fei Ai Za Zhi. 2019 Aug 20;22(8):500-506
pubmed: 31451140
Nat Med. 2020 Dec;26(12):1839-1844
pubmed: 33046870
PLoS One. 2019 Nov 19;14(11):e0224430
pubmed: 31743333
J Hepatol. 2019 Jan;70(1):58-65
pubmed: 30213589
Semin Immunopathol. 2019 Jan;41(1):125-131
pubmed: 30006738
Front Immunol. 2017 Jul 21;8:830
pubmed: 28785261
Nat Immunol. 2015 Dec;16(12):1235-44
pubmed: 26502405
Front Immunol. 2016 Nov 09;7:491
pubmed: 27881983
Oncoimmunology. 2020 Feb 17;9(1):1724763
pubmed: 32117589
Immunol Rev. 2016 May;271(1):260-75
pubmed: 27088920
Int Immunopharmacol. 2021 May;94:107416
pubmed: 33676174
Adv Exp Med Biol. 2018;1092:69-90
pubmed: 30368749
Clin Cancer Res. 2020 Aug 15;26(16):4381-4389
pubmed: 32269054
Cancer Immunol Res. 2020 Nov;8(11):1338-1345
pubmed: 33139300
J Immunol. 2017 Apr 1;198(7):2602-2611
pubmed: 28235864
Am J Respir Crit Care Med. 2014 Apr 1;189(7):832-44
pubmed: 24484236
Cancer Immunol Immunother. 2019 Nov;68(11):1733-1745
pubmed: 31598757
J Natl Compr Canc Netw. 2017 Apr;15(4):504-535
pubmed: 28404761
Zhongguo Fei Ai Za Zhi. 2017 Jun 20;20(6):382-388
pubmed: 28641695
Front Immunol. 2021 Jun 30;12:698604
pubmed: 34276690